Euromit 7

The 7th European Meeting on Mitochondrial Pathology

Stockholm Sweden June 11-14, 2008

Note: Dealine for registration has been changed to May 8, 2008.
Dealine for abstract submission has been changed to
May 15, 2008.


Dear Colleague,

It is our pleasure to welcome you to
Stockholm Sweden and the seventh European Meeting on Mitochondrial Pathology! This symposium is organized every three-four years in Europe and has brought forward recent advances in the field of mitochondrial research. Since the first Euromit meeting the research field has undergone a remarkable expansion, and mitochondrial dysfunction is today recognized as an important factor in human disease. Mitochondrial dysfunction has been implicated not only in rare genetic disorders, but also in several common health problems such as diabetes, cancer and neurodegeneration, as well as in the aging process. Even so, there is still much remaining to be discovered, both regarding the normal function of mitochondria, as well as the mechanisms by which they can cause disease.

The meeting is composed of a keynote lecture, plenary sessions, short oral presentations, and poster sessions. Our intention is that this meeting will catalyze and facilitate constructive scientific interactions and collaborations.

We have very high hopes for this meeting, and hope to meet you at the the seventh European Meeting on Mitochondrial Pathology.

Warm Welcome!

Nils-Göran Larsson and Claes Gustafsson
Local organizing committee
Division of metabolic diseases
Department of laboratory medicine
Karolinska Institutet

The legacy of Marie Schlau: literature to help cure Friedreich's Ataxia

If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.

The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.

Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!


Research projects currently being financed by BabelFAmily

Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:

1) Gene Therapy for Friedreich's Ataxia research project:

The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.

2) Frataxin delivery research project:
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.

The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.



Go to top